A Pitch Perfect Miniseries | #3 Bioreactors don't do beta versions and why tech VCs are out of their league with bio ft. Capricorn Partners
Send us Fan Mail Recorded live at the Pitch Perfect Bioeconomy event in Brussels, this episode features Rob van der Meij, Partner at Capricorn Partners, on what it really takes to scale bio-based innovation. The key message? Scaling bio is not like scaling software. As an investor who has helped grow multiple tech-driven companies, Rob breaks down why process development is the most underestimated factor in bio-based scale-up. In digital, you can iterate fast. In bio-based manufacturing, scale-up is sequential, capital-intensive, and often more art than science. We dive into: Why process data matters more than pitch decks Why rushing scale can destroy value Why MVP thinking doesn’t work in industrial biotech When equity, grants, debt, and government-backed loans make sense Why the right investor mix is critical in early phases In bio-based industries, 90% of the cost is defined in the first 10% of a capital project. Speed matters, but pushing at the wrong moment can cost years. For founders and investors navigating long R&D cycles, heavy CapEx, and patient capital, this is a grounded conversation about reality versus hype. If you’re building in the bioeconomy, this episode is a must-listen. This episode is powered by Bio Base Europe Pilot Plant. Support the show
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
